Interleukin-6 signaling pathway and its role in kidney disease: An update

Frontiers in Immunology

Volumn 8, Issue APR, 2017, Pages

  Su, Hua ^a   Lei, Chun Tao ^a   Zhang, Chun ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Endothelial cells; IL 6 classic signaling; IL 6 trans signaling; Mesangial cells; Podocyte; Renal disease; Tubular epithelial cells

Indexed keywords

INTERLEUKIN 6; MITOGEN ACTIVATED PROTEIN KINASE;

ACUTE KIDNEY FAILURE; ATHEROSCLEROSIS; AUTOIMMUNE DISEASE; CHRONIC KIDNEY FAILURE; DIABETIC NEPHROPATHY; DNA POLYMORPHISM; END STAGE RENAL DISEASE; ENDOTHELIUM CELL; HEMATOPOIESIS; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; INFLAMMATION; INTRACELLULAR SIGNALING; KIDNEY DISEASE; KIDNEY TUBULE CELL; LUPUS ERYTHEMATOSUS NEPHRITIS; MACROPHAGE; MALIGNANT NEOPLASM; MEMBRANOPROLIFERATIVE GLOMERULONEPHRITIS; MESANGIUM CELL; MICROANGIOPATHY; ORGANOGENESIS; REVIEW; T LYMPHOCYTE; TH17 CELL;

EID: 85018447093     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2017.00405     Document Type: Review

References (155)

1. Hirano T, Yasukawa K, Harada H, Taga T, Watanabe Y, Matsuda T, et al. Complementary DNA for a novel human interleukin (BSF-2) that induces B lymphocytes to produce immunoglobulin. Nature (1986) 324:73-6. doi: 10.1038/324073a0
2. Hirano T. Interleukin 6 and its receptor: ten years later. Int Rev Immunol (1998) 16:249-84. doi:10.3109/08830189809042997
3. Heinrich PC, Behrmann I, Haan S, Hermanns HM, Muller-Newen G, Schaper F. Principles of interleukin (IL)-6-type cytokine signalling and its regulation. Biochem J (2003) 374:1-20. doi:10.1042/BJ20030407
4. Scheller J, Grötzinger J, Rose-John S. Updating interleukin-6 classic-and trans-signaling. Signal Transduct (2006) 6:240-59. doi:10.1002/sita.200600086
5. Costa-Pereira AP. Regulation of IL-6-type cytokine responses by MAPKs. Biochem Soc Trans (2014) 42:59-62. doi:10.1042/BST20130267
6. Garbers C, Hermanns HM, Schaper F, Muller-Newen G, Grotzinger J, Rose-John S, et al. Plasticity and cross-talk of interleukin 6-type cytokines. Cytokine Growth Factor Rev (2012) 23:85-97. doi:10.1016/j.cytogfr.2012.04.001
7. Dorner AJ, Goldman SJ, Keith JC Jr. Interleukin-11. BioDrugs (1997) 8:418-29. doi:10.2165/00063030-199708060-00002
8. Peters M, Odenthal M, Schirmacher P, Blessing M, Fattori E, Ciliberto G, et al. Soluble IL-6 receptor leads to a paracrine modulation of the IL-6-induced hepatic acute phase response in double transgenic mice. J Immunol (1997) 159:1474-81
9. Chodorowska G, Glowacka A, Tomczyk M. Leukemia inhibitory factor (LIF) and its biological activity. Ann Univ Mariae Curie Sklodowska Med (2004) 59:189-93
10. Tamura T, Udagawa N, Takahashi N, Miyaura C, Tanaka S, Yamada Y, et al. Soluble interleukin-6 receptor triggers osteoclast formation by interleukin 6. Proc Natl Acad Sci U S A (1993) 90:11924-8. doi:10.1073/pnas.90.24.11924
11. Richards CD, Langdon C, Deschamps P, Pennica D, Shaughnessy SG. Stimulation of osteoclast differentiation in vitro by mouse oncostatin M, leukaemia inhibitory factor, cardiotrophin-1 and interleukin 6: synergy with dexamethasone. Cytokine (2000) 12:613-21. doi:10.1006/cyto.1999.0635
12. Fukada T, Hibi M, Yamanaka Y, Takahashi-Tezuka M, Fujitani Y, Yamaguchi T, et al. Two signals are necessary for cell proliferation induced by a cytokine receptor gp130: involvement of STAT3 in anti-apoptosis. Immunity (1996) 5:449-60. doi:10.1016/S1074-7613(00)80501-4
13. Ohtani T, Ishihara K, Atsumi T, Nishida K, Kaneko Y, Miyata T, et al. Dissection of signaling cascades through gp130 in vivo: reciprocal roles for STAT3-and SHP2-mediated signals in immune responses. Immunity (2000) 12:95-105. doi:10.1016/S1074-7613(00)80162-4
14. Kamimura D, Ishihara K, Hirano T. IL-6 signal transduction and its physiological roles: the signal orchestration model. Rev Physiol Biochem Pharmacol (2003) 149:1-38. doi:10.1007/s10254-003-0012-2
15. Moutabarrik A, Nakanishi I, Ishibashi M. Interleukin-6 and interleukin-6 receptor are expressed by cultured glomerular epithelial cells. Scand J Immunol (1994) 40:181-6. doi:10.1111/j.1365-3083.1994.tb03448.x
16. Oberg HH, Wesch D, Grussel S, Rose-John S, Kabelitz D. Differential expression of CD126 and CD130 mediates different STAT-3 phosphorylation in CD4+CD25-and CD25high regulatory T cells. Int Immunol (2006) 18:555-63. doi:10.1093/intimm/dxh396
17. Orlando S, Sironi M, Bianchi G, Drummond AH, Boraschi D, Yabes D, et al. Role of metalloproteases in the release of the IL-1 type II decoy receptor. J Biol Chem (1997) 272:31764-9. doi:10.1074/jbc.272.50.31764
18. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, et al. An essential role for ectodomain shedding in mammalian development. Science (1998) 282:1281-4. doi:10.1126/science.282.5392.1281
19. Reddy P, Slack JL, Davis R, Cerretti DP, Kozlosky CJ, Blanton RA, et al. Functional analysis of the domain structure of tumor necrosis factor-alpha converting enzyme. J Biol Chem (2000) 275:14608-14. doi:10.1074/jbc.275.19.14608
20. Novick D, Engelmann H, Wallach D, Rubinstein M. Soluble cytokine receptors are present in normal human urine. J Exp Med (1989) 170:1409-14. doi:10.1084/jem.170.4.1409
21. Atsumi T, Ishihara K, Kamimura D, Ikushima H, Ohtani T, Hirota S, et al. A point mutation of Tyr-759 in interleukin 6 family cytokine receptor subunit gp130 causes autoimmune arthritis. J Exp Med (2002) 196:979-90. doi:10.1084/jem.20020619
22. Scheller J, Rose-John S. Interleukin-6 and its receptor: from bench to bedside. Med Microbiol Immunol (2006) 195:173-83. doi:10.1007/s00430-006-0019-9
23. Rose-John S, Waetzig GH, Scheller J, Grotzinger J, Seegert D. The IL-6/sIL-6R complex as a novel target for therapeutic approaches. Expert Opin Ther Targets (2007) 11:613-24. doi:10.1517/14728222.11.5.613
24. Li H, Rokavec M, Hermeking H. Soluble IL6R represents a miR-34a target: potential implications for the recently identified IL-6R/STAT3/miR-34a feed-back loop. Oncotarget (2015) 6:14026-32. doi:10.18632/oncotarget.4334
25. Zhuang PY, Wang JD, Tang ZH, Zhou XP, Quan ZW, Liu YB, et al. Higher proliferation of peritumoral endothelial cells to IL-6/sIL-6R than tumoral endothelial cells in hepatocellular carcinoma. BMC Cancer (2015) 15:830. doi:10.1186/s12885-015-1763-2
26. Rose-John S, Heinrich PC. Soluble receptors for cytokines and growth factors: generation and biological function. Biochem J (1994) 300(Pt 2):281-90. doi:10.1042/bj3000281
27. Ebihara N, Matsuda A, Nakamura S, Matsuda H, Murakami A. Role of the IL-6 classic-and trans-signaling pathways in corneal sterile inflammation and wound healing. Invest Ophthalmol Vis Sci (2011) 52:8549-57. doi:10.1167/iovs.11-7956
28. Malchow S, Thaiss W, Janner N, Waetzig GH, Gewiese-Rabsch J, Garbers C, et al. Essential role of neutrophil mobilization in concanavalin A-induced hepatitis is based on classic IL-6 signaling but not on IL-6 trans-signaling. Biochim Biophys Acta (2011) 1812:290-301. doi:10.1016/j.bbadis.2010.11.009
29. Rothaug M, Becker-Pauly C, Rose-John S. The role of interleukin-6 signaling in nervous tissue. Biochim Biophys Acta (2016) 1863:1218-27. doi:10.1016/j.bbamcr.2016.03.018
30. Lust JA, Donovan KA, Kline MP, Greipp PR, Kyle RA, Maihle NJ. Isolation of an mRNA encoding a soluble form of the human interleukin-6 receptor. Cytokine (1992) 4:96-100. doi:10.1016/1043-4666(92)90043-Q
31. Mullberg J, Schooltink H, Stoyan T, Gunther M, Graeve L, Buse G, et al. The soluble interleukin-6 receptor is generated by shedding. Eur J Immunol (1993) 23:473-80. doi:10.1002/eji.1830230226
32. Lamas JR, Rodriguez-Rodriguez L, Tornero-Esteban P, Villafuertes E, Hoyas J, Abasolo L, et al. Alternative splicing and proteolytic rupture contribute to the generation of soluble IL-6 receptors (sIL-6R) in rheumatoid arthritis. Cytokine (2013) 61:720-3. doi:10.1016/j.cyto.2012.12.025
33. Dimitrov S, Lange T, Benedict C, Nowell MA, Jones SA, Scheller J, et al. Sleep enhances IL-6 trans-signaling in humans. FASEB J (2006) 20:2174-6. doi:10.1096/fj.06-5754fje
34. Chalaris A, Rabe B, Paliga K, Lange H, Laskay T, Fielding CA, et al. Apoptosis is a natural stimulus of IL6R shedding and contributes to the proinflammatory trans-signaling function of neutrophils. Blood (2007) 110:1748-55. doi:10.1182/blood-2007-01-067918
35. Chalaris A, Gewiese J, Paliga K, Fleig L, Schneede A, Krieger K, et al. ADAM17-mediated shedding of the IL6R induces cleavage of the membrane stub by gamma-secretase. Biochim Biophys Acta (2010) 1803:234-45. doi:10.1016/j.bbamcr.2009.12.001
36. Matthews V, Schuster B, Schutze S, Bussmeyer I, Ludwig A, Hundhausen C, et al. Cellular cholesterol depletion triggers shedding of the human interleukin-6 receptor by ADAM10 and ADAM17 (TACE). J Biol Chem (2003) 278:38829-39. doi:10.1074/jbc.M210584200
37. Walev I, Vollmer P, Palmer M, Bhakdi S, Rose-John S. Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide. Proc Natl Acad Sci U S A (1996) 93:7882-7. doi:10.1073/pnas.93.15.7882
38. Franchimont N, Lambert C, Huynen P, Ribbens C, Relic B, Chariot A, et al. Interleukin-6 receptor shedding is enhanced by interleukin-1beta and tumor necrosis factor alpha and is partially mediated by tumor necrosis factor alpha-converting enzyme in osteoblast-like cells. Arthritis Rheum (2005) 52:84-93. doi:10.1002/art.20727
39. Vahdat AM, Reiners KS, Simhadri VL, Eichenauer DA, Boll B, Chalaris A, et al. TNF-alpha-converting enzyme (TACE/ADAM17)-dependent loss of CD30 induced by proteasome inhibition through reactive oxygen species. Leukemia (2010) 24:51-7. doi:10.1038/leu.2009.230
40. Schumacher N, Meyer D, Mauermann A, Von Der Heyde J, Wolf J, Schwarz J, et al. Shedding of endogenous interleukin-6 receptor (IL-6R) is governed by a disintegrin and metalloproteinase (ADAM) proteases while a full-length IL-6R isoform localizes to circulating microvesicles. J Biol Chem (2015) 290:26059-71. doi:10.1074/jbc.M115.649509
41. Narazaki M, Yasukawa K, Saito T, Ohsugi Y, Fukui H, Koishihara Y, et al. Soluble forms of the interleukin-6 signal-transducing receptor component gp130 in human serum possessing a potential to inhibit signals through membrane-anchored gp130. Blood (1993) 82:1120-6
42. Zhang JG, Zhang Y, Owczarek CM, Ward LD, Moritz RL, Simpson RJ, et al. Identification and characterization of two distinct truncated forms of gp130 and a soluble form of leukemia inhibitory factor receptor alpha-chain in normal human urine and plasma. J Biol Chem (1998) 273:10798-805. doi:10.1074/jbc.273.17.10798
43. Tanaka M, Kishimura M, Ozaki S, Osakada F, Hashimoto H, Okubo M, et al. Cloning of novel soluble gp130 and detection of its neutralizing autoantibodies in rheumatoid arthritis. J Clin Invest (2000) 106:137-44. doi:10.1172/JCI7479
44. Vardam TD, Zhou L, Appenheimer MM, Chen Q, Wang WC, Baumann H, et al. Regulation of a lymphocyte-endothelial-IL-6 trans-signaling axis by fever-range thermal stress: hot spot of immune surveillance. Cytokine (2007) 39:84-96. doi:10.1016/j.cyto.2007.07.184
45. Mullberg J, Dittrich E, Graeve L, Gerhartz C, Yasukawa K, Taga T, et al. Differential shedding of the two subunits of the interleukin-6 receptor. FEBS Lett (1993) 332:174-8. doi:10.1016/0014-5793(93)80507-Q
46. Jostock T, Mullberg J, Ozbek S, Atreya R, Blinn G, Voltz N, et al. Soluble gp130 is the natural inhibitor of soluble interleukin-6 receptor transsignaling responses. Eur J Biochem (2001) 268:160-7. doi:10.1046/j.1432-1327.2001.01867.x
47. Moreno Velasquez I, Golabkesh Z, Kallberg H, Leander K, De Faire U, Gigante B. Circulating levels of interleukin 6 soluble receptor and its natural antagonist, sgp130, and the risk of myocardial infarction. Atherosclerosis (2015) 240:477-81. doi:10.1016/j.atherosclerosis.2015.04.014
48. Hui W, Bell M, Carroll G. Soluble glycoprotein 130 (gp130) attenuates OSM-and LIF-induced cartilage proteoglycan catabolism. Cytokine (2000) 12:151-5. doi:10.1006/cyto.1999.0550
49. Scheller J, Schuster B, Holscher C, Yoshimoto T, Rose-John S. No inhibition of IL-27 signaling by soluble gp130. Biochem Biophys Res Commun (2005) 326:724-8. doi:10.1016/j.bbrc.2004.11.098
50. Waetzig GH, Rose-John S. Hitting a complex target: an update on interleukin-6 trans-signalling. Expert Opin Ther Targets (2012) 16:225-36. doi:10.1517/14728222.2012.660307
51. Scheller J, Chalaris A, Schmidt-Arras D, Rose-John S. The pro-and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta (2011) 1813:878-88. doi:10.1016/j.bbamcr.2011.01.034
52. Tilg H, Dinarello CA, Mier JW. IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today (1997) 18:428-32. doi:10.1016/S0167-5699(97)01103-1
53. Atreya R, Mudter J, Finotto S, Mullberg J, Jostock T, Wirtz S, et al. Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo. Nat Med (2000) 6:583-8. doi:10.1038/75068
54. Mitsuyama K, Matsumoto S, Rose-John S, Suzuki A, Hara T, Tomiyasu N, et al. STAT3 activation via interleukin 6 trans-signalling contributes to ileitis in SAMP1/Yit mice. Gut (2006) 55:1263-9. doi:10.1136/gut.2005.079343
55. Finotto S, Eigenbrod T, Karwot R, Boross I, Doganci A, Ito H, et al. Local blockade of IL-6R signaling induces lung CD4+ T cell apoptosis in a murine model of asthma via regulatory T cells. Int Immunol (2007) 19:685-93. doi:10.1093/intimm/dxm037
56. Rabe B, Chalaris A, May U, Waetzig GH, Seegert D, Williams AS, et al. Transgenic blockade of interleukin 6 transsignaling abrogates inflammation. Blood (2008) 111:1021-8. doi:10.1182/blood-2007-07-102137
57. Matsumoto S, Hara T, Mitsuyama K, Yamamoto M, Tsuruta O, Sata M, et al. Essential roles of IL-6 trans-signaling in colonic epithelial cells, induced by the IL-6/soluble-IL-6 receptor derived from lamina propria macrophages, on the development of colitis-associated premalignant cancer in a murine model. J Immunol (2010) 184:1543-51. doi:10.4049/jimmunol.0801217
58. Greenhill CJ, Rose-John S, Lissilaa R, Ferlin W, Ernst M, Hertzog PJ, et al. IL-6 trans-signaling modulates TLR4-dependent inflammatory responses via STAT3. J Immunol (2011) 186:1199-208. doi:10.4049/jimmunol.1002971
59. Lesina M, Kurkowski MU, Ludes K, Rose-John S, Treiber M, Kloppel G, et al. Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. Cancer Cell (2011) 19:456-69. doi:10.1016/j.ccr.2011.03.009
60. Lo CW, Chen MW, Hsiao M, Wang S, Chen CA, Hsiao SM, et al. IL-6 trans-signaling in formation and progression of malignant ascites in ovarian cancer. Cancer Res (2011) 71:424-34. doi:10.1158/0008-5472
61. Jasiewicz M, Knapp M, Waszkiewicz E, Ptaszynska-Kopczynska K, Szpakowicz A, Sobkowicz B, et al. Enhanced IL-6 trans-signaling in pulmonary arterial hypertension and its potential role in disease-related systemic damage. Cytokine (2015) 76:187-92. doi:10.1016/j.cyto.2015.06.018
62. Kaplanski G, Marin V, Montero-Julian F, Mantovani A, Farnarier C. IL-6: a regulator of the transition from neutrophil to monocyte recruitment during inflammation. Trends Immunol (2003) 24:25-9. doi:10.1016/S1471-4906(02)00013-3
63. Bettelli E, Carrier Y, Gao W, Korn T, Strom TB, Oukka M, et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature (2006) 441:235-8. doi:10.1038/nature04753
64. Mangan PR, Harrington LE, O'Quinn DB, Helms WS, Bullard DC, Elson CO, et al. Transforming growth factor-beta induces development of the T(H)17 lineage. Nature (2006) 441:231-4. doi:10.1038/nature04754
65. Veldhoen M, Hocking RJ, Atkins CJ, Locksley RM, Stockinger B. TGFbeta in the context of an inflammatory cytokine milieu supports de novo differentiation of IL-17-producing T cells. Immunity (2006) 24:179-89. doi:10.1016/j.immuni.2006.01.001
66. Kimura A, Kishimoto T. Th17 cells in inflammation. Int Immunopharmacol (2011) 11:319-22. doi:10.1016/j.intimp.2010.10.004
67. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, et al. Conversion of peripheral CD4+CD25-naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med (2003) 198:1875-86. doi:10.1084/jem.20030152
68. Fantini MC, Becker C, Monteleone G, Pallone F, Galle PR, Neurath MF. Cutting edge: TGF-beta induces a regulatory phenotype in CD4+CD25-T cells through Foxp3 induction and down-regulation of Smad7. J Immunol (2004) 172:5149-53. doi:10.4049/jimmunol.172.9.5149
69. Dominitzki S, Fantini MC, Neufert C, Nikolaev A, Galle PR, Scheller J, et al. Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells. J Immunol (2007) 179:2041-5. doi:10.4049/jimmunol.179.4.2041
70. Fujimoto M, Nakano M, Terabe F, Kawahata H, Ohkawara T, Han Y, et al. The influence of excessive IL-6 production in vivo on the development and function of Foxp3+ regulatory T cells. J Immunol (2011) 186:32-40. doi:10.4049/jimmunol.0903314
71. Teague TK, Marrack P, Kappler JW, Vella AT. IL-6 rescues resting mouse T cells from apoptosis. J Immunol (1997) 158:5791-6
72. Yoshida H, Hashizume M, Suzuki M, Mihara M. Anti-IL-6 receptor antibody suppressed T cell activation by inhibiting IL-2 production and inducing regulatory T cells. Eur J Pharmacol (2010) 634:178-83. doi:10.1016/j.ejphar.2010.02.026
73. Rincon M, Anguita J, Nakamura T, Fikrig E, Flavell RA. Interleukin (IL)-6 directs the differentiation of IL-4-producing CD4+ T cells. J Exp Med (1997) 185:461-9. doi:10.1084/jem.185.3.461
74. Linterman MA, Vinuesa CG. Signals that influence T follicular helper cell differentiation and function. Semin Immunopathol (2010) 32:183-96. doi:10.1007/s00281-009-0194-z
75. Griendling KK, Sorescu D, Lassegue B, Ushio-Fukai M. Modulation of protein kinase activity and gene expression by reactive oxygen species and their role in vascular physiology and pathophysiology. Arterioscler Thromb Vasc Biol (2000) 20:2175-83. doi:10.1161/01.ATV.20.10.2175
76. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol (2003) 91:7A-11A. doi:10.1016/S0002-9149(02)03144-2
77. Mitani H, Katayama N, Araki H, Ohishi K, Kobayashi K, Suzuki H, et al. Activity of interleukin 6 in the differentiation of monocytes to macrophages and dendritic cells. Br J Haematol (2000) 109:288-95. doi:10.1046/j.1365-2141.2000.02020.x
78. Krishnaraju K, Hoffman B, Liebermann DA. The zinc finger transcription factor Egr-1 activates macrophage differentiation in M1 myeloblastic leukemia cells. Blood (1998) 92:1957-66
79. Chomarat P, Banchereau J, Davoust J, Palucka AK. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol (2000) 1:510-4. doi:10.1038/82763
80. Tanaka H, Matsumura I, Nakajima K, Daino H, Sonoyama J, Yoshida H, et al. GATA-1 blocks IL-6-induced macrophage differentiation and apoptosis through the sustained expression of cyclin D1 and bcl-2 in a murine myeloid cell line M1. Blood (2000) 95:1264-73
81. Biswas P, Delfanti F, Bernasconi S, Mengozzi M, Cota M, Polentarutti N, et al. Interleukin-6 induces monocyte chemotactic protein-1 in peripheral blood mononuclear cells and in the U937 cell line. Blood (1998) 91:258-65
82. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, et al. A central role for Stat3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J (1996) 15:3651-8
83. Yamanaka Y, Nakajima K, Fukada T, Hibi M, Hirano T. Differentiation and growth arrest signals are generated through the cytoplasmic region of gp130 that is essential for Stat3 activation. EMBO J (1996) 15:1557-65
84. Kopf M, Baumann H, Freer G, Freudenberg M, Lamers M, Kishimoto T, et al. Impaired immune and acute-phase responses in interleukin-6-deficient mice. Nature (1994) 368:339-42. doi:10.1038/368339a0
85. Tanaka T, Akira S, Yoshida K, Umemoto M, Yoneda Y, Shirafuji N, et al. Targeted disruption of the NF-IL6 gene discloses its essential role in bacteria killing and tumor cytotoxicity by macrophages. Cell (1995) 80:353-61. doi:10.1016/0092-8674(95)90418-2
86. Akira S, Kishimoto T. Role of interleukin-6 in macrophage function. Curr Opin Hematol (1996) 3:87-93. doi:10.1097/00062752-199603010-00013
87. Coletta I, Soldo L, Polentarutti N, Mancini F, Guglielmotti A, Pinza M, et al. Selective induction of MCP-1 in human mesangial cells by the IL-6/sIL-6R complex. Exp Nephrol (2000) 8:37-43. doi:10.1159/000059327
88. Nechemia-Arbely Y, Barkan D, Pizov G, Shriki A, Rose-John S, Galun E, et al. IL-6/IL-6R axis plays a critical role in acute kidney injury. J Am Soc Nephrol (2008) 19:1106-15. doi:10.1681/ASN.2007070744
89. Feng X, Lu TC, Chuang PY, Fang W, Ratnam K, Xiong H, et al. Reduction of Stat3 activity attenuates HIV-induced kidney injury. J Am Soc Nephrol (2009) 20:2138-46. doi:10.1681/ASN.2008080879
90. Lu TC, Wang ZH, Feng X, Chuang PY, Fang W, Shen Y, et al. Knockdown of Stat3 activity in vivo prevents diabetic glomerulopathy. Kidney Int (2009) 76:63-71. doi:10.1038/ki.2009.98
91. Dai Y, Gu L, Yuan W, Yu Q, Ni Z, Ross MJ, et al. Podocyte-specific deletion of signal transducer and activator of transcription 3 attenuates nephrotoxic serum-induced glomerulonephritis. Kidney Int (2013) 84:950-61. doi:10.1038/ki.2013.197
92. Gohda T, Makita Y, Shike T, Funabiki K, Shirato I, Tomino Y. Dilazep hydrochloride, an antiplatelet drug, inhibits lipopolysaccharide-induced mouse mesangial cell IL-6 secretion and proliferation. Kidney Blood Press Res (2001) 24:33-8. doi:10.1159/000054203
93. Lu H, Zhou J. HBV X gene transfection upregulates IL-1beta and IL-6 gene expression and induces rat glomerular mesangial cell proliferation. J Huazhong Univ Sci Technolog Med Sci (2008) 28:247-50. doi:10.1007/s11596-008-0304-5
94. Wassmann S, Stumpf M, Strehlow K, Schmid A, Schieffer B, Bohm M, et al. Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res (2004) 94:534-41. doi:10.1161/01.RES.0000115557.25127.8D
95. Schrader LI, Kinzenbaw DA, Johnson AW, Faraci FM, Didion SP. IL-6 deficiency protects against angiotensin II induced endothelial dysfunction and hypertrophy. Arterioscler Thromb Vasc Biol (2007) 27:2576-81. doi:10.1161/ATVBAHA.107.153080
96. Ranganathan P, Jayakumar C, Ramesh G. Proximal tubule-specific overexpression of netrin-1 suppresses acute kidney injury-induced interstitial fibrosis and glomerulosclerosis through suppression of IL-6/STAT3 signaling. Am J Physiol Renal Physiol (2013) 304:F1054-65. doi:10.1152/ajprenal.00650.2012
97. Kielar ML, John R, Bennett M, Richardson JA, Shelton JM, Chen L, et al. Maladaptive role of IL-6 in ischemic acute renal failure. J Am Soc Nephrol (2005) 16:3315-25. doi:10.1681/ASN.2003090757
98. Harcourt BE, Forbes JM, Matthews VB. Obesity-induced renal impairment is exacerbated in interleukin-6-knockout mice. Nephrology (Carlton) (2012) 17:257-62. doi:10.1111/j.1440-1797.2011.01547.x
99. Lee SJ, Borsting E, Decleves AE, Singh P, Cunard R. Podocytes express IL-6 and lipocalin 2/neutrophil gelatinase-associated lipocalin in lipopolysaccharide-induced acute glomerular injury. Nephron Exp Nephrol (2012) 121:e86-96. doi:10.1159/000345151
100. Kim DI, Park SH. Sequential signaling cascade of IL-6 and PGC-1alpha is involved in high glucose-induced podocyte loss and growth arrest. Biochem Biophys Res Commun (2013) 435:702-7. doi:10.1016/j.bbrc.2013.05.046
101. Srivastava T, Sharma M, Yew KH, Sharma R, Duncan RS, Saleem MA, et al. LPS and PAN-induced podocyte injury in an in vitro model of minimal change disease: changes in TLR profile. J Cell Commun Signal (2013) 7:49-60. doi:10.1007/s12079-012-0184-0
102. Abkhezr M, Dryer SE. Angiotensin II and canonical transient receptor potential-6 activation stimulate release of a signal transducer and activator of transcription 3-activating factor from mouse podocytes. Mol Pharmacol (2014) 86:150-8. doi:10.1124/mol.114.092536
103. Xing CY, Saleem MA, Coward RJ, Ni L, Witherden IR, Mathieson PW. Direct effects of dexamethasone on human podocytes. Kidney Int (2006) 70:1038-45. doi:10.1038/sj.ki.5001655
104. Matsumoto T, Hess S, Kajiyama H, Sakairi T, Saleem MA, Mathieson PW, et al. Proteomic analysis identifies insulin-like growth factor-binding protein-related protein-1 as a podocyte product. Am J Physiol Renal Physiol (2010) 299:F776-84. doi:10.1152/ajprenal.00597.2009
105. Sanchez-Nino MD, Bozic M, Cordoba-Lanus E, Valcheva P, Gracia O, Ibarz M, et al. Beyond proteinuria: VDR activation reduces renal inflammation in experimental diabetic nephropathy. Am J Physiol Renal Physiol (2012) 302:F647-57. doi:10.1152/ajprenal.00090.2011
106. Anderson M, Roshanravan H, Khine J, Dryer SE. Angiotensin II activation of TRPC6 channels in rat podocytes requires generation of reactive oxygen species. J Cell Physiol (2014) 229:434-42. doi:10.1002/jcp.24461
107. Arakawa T, Masaki T, Hirai T, Doi S, Kuratsune M, Arihiro K, et al. Activation of signal transducer and activator of transcription 3 correlates with cell proliferation and renal injury in human glomerulonephritis. Nephrol Dial Transplant (2008) 23:3418-26. doi:10.1093/ndt/gfn314
108. Kuravi SJ, Mcgettrick HM, Satchell SC, Saleem MA, Harper L, Williams JM, et al. Podocytes regulate neutrophil recruitment by glomerular endothelial cells via IL-6-mediated crosstalk. J Immunol (2014) 193:234-43. doi:10.4049/jimmunol.1300229
109. Song L, Schindler C. IL-6 and the acute phase response in murine atherosclerosis. Atherosclerosis (2004) 177:43-51. doi:10.1016/j.atherosclerosis.2004.06.018
110. Pfafflin A, Brodbeck K, Heilig CW, Haring HU, Schleicher ED, Weigert C. Increased glucose uptake and metabolism in mesangial cells overexpressing glucose transporter 1 increases interleukin-6 and vascular endothelial growth factor production: role of AP-1 and HIF-1alpha. Cell Physiol Biochem (2006) 18:199-210. doi:10.1159/000097667
111. Schmitt R, Stahl AL, Olin AI, Kristoffersson AC, Rebetz J, Novak J, et al. The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy. J Immunol (2014) 193:317-26. doi:10.4049/jimmunol.1302249
112. Ji M, Lu Y, Zhao C, Gao W, He F, Zhang J, et al. C5a induces the synthesis of IL-6 and TNF-alpha in rat glomerular mesangial cells through MAPK signaling pathways. PLoS One (2016) 11:e0161867. doi:10.1371/journal.pone.0161867
113. Sironi M, Breviario F, Proserpio P, Biondi A, Vecchi A, Van Damme J, et al. IL-1 stimulates IL-6 production in endothelial cells. J Immunol (1989) 142:549-53
114. Romano M, Sironi M, Toniatti C, Polentarutti N, Fruscella P, Ghezzi P, et al. Role of IL-6 and its soluble receptor in induction of chemokines and leukocyte recruitment. Immunity (1997) 6:315-25. doi:10.1016/S1074-7613(00)80334-9
115. Yung S, Tsang RC, Sun Y, Leung JK, Chan TM. Effect of human anti-DNA antibodies on proximal renal tubular epithelial cell cytokine expression: implications on tubulointerstitial inflammation in lupus nephritis. J Am Soc Nephrol (2005) 16:3281-94. doi:10.1681/ASN.2004110917
116. Gomez-Guerrero C, Lopez-Armada MJ, Gonzalez E, Egido J. Soluble IgA and IgG aggregates are catabolized by cultured rat mesangial cells and induce production of TNF-alpha and IL-6, and proliferation. J Immunol (1994) 153:5247-55
117. Moura IC, Arcos-Fajardo M, Gdoura A, Leroy V, Sadaka C, Mahlaoui N, et al. Engagement of transferrin receptor by polymeric IgA1: evidence for a positive feedback loop involving increased receptor expression and mesangial cell proliferation in IgA nephropathy. J Am Soc Nephrol (2005) 16:2667-76. doi:10.1681/ASN.2004111006
118. Tamouza H, Chemouny JM, Raskova Kafkova L, Berthelot L, Flamant M, Demion M, et al. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy. Kidney Int (2012) 82:1284-96. doi:10.1038/ki.2012.192
119. Zhang J, Li Y, Shan K, Wang L, Qiu W, Lu Y, et al. Sublytic C5b-9 induces IL-6 and TGF-beta1 production by glomerular mesangial cells in rat Thy-1 nephritis through p300-mediated C/EBPbeta acetylation. FASEB J (2014) 28:1511-25. doi:10.1096/fj.13-242693
120. Linker-Israeli M, Deans RJ, Wallace DJ, Prehn J, Ozeri-Chen T, Klinenberg JR. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol (1991) 147:117-23
121. Peterson E, Robertson AD, Emlen W. Serum and urinary interleukin-6 in systemic lupus erythematosus. Lupus (1996) 5:571-5. doi:10.1177/096120339600500603
122. Cash H, Relle M, Menke J, Brochhausen C, Jones SA, Topley N, et al. Interleukin 6 (IL-6) deficiency delays lupus nephritis in MRL-Faslpr mice: the IL-6 pathway as a new therapeutic target in treatment of autoimmune kidney disease in systemic lupus erythematosus. J Rheumatol (2010) 37:60-70. doi:10.3899/jrheum.090194
123. Ball EM, Gibson DS, Bell AL, Rooney MR. Plasma IL-6 levels correlate with clinical and ultrasound measures of arthritis in patients with systemic lupus erythematosus. Lupus (2014) 23:46-56. doi:10.1177/0961203313512882
124. Abdel Galil SM, Ezzeldin N, El-Boshy ME. The role of serum IL-17 and IL-6 as biomarkers of disease activity and predictors of remission in patients with lupus nephritis. Cytokine (2015) 76:280-7. doi:10.1007/BF02253829
125. Solus JF, Chung CP, Oeser A, Li C, Rho YH, Bradley KM, et al. Genetics of serum concentration of IL-6 and TNFalpha in systemic lupus erythematosus and rheumatoid arthritis: a candidate gene analysis. Clin Rheumatol (2015) 34:1375-82. doi:10.1007/s10067-015-2881-6
126. Wang JB, Li H, Wang LL, Liang HD, Zhao L, Dong J. Role of IL-1beta, IL-6, IL-8 and IFN-gamma in pathogenesis of central nervous system neuropsychiatric systemic lupus erythematous. Int J Clin Exp Med (2015) 8:16658-63
127. Garaud S, Le Dantec C, Jousse-Joulin S, Hanrotel-Saliou C, Saraux A, Mageed RA, et al. IL-6 modulates CD5 expression in B cells from patients with lupus by regulating DNA methylation. J Immunol (2009) 182:5623-32. doi:10.4049/jimmunol.0802412
128. Huang CM, Huo AP, Tsai CH, Chen CL, Tsai FJ. Lack of association of interleukin-6 and interleukin-8 gene polymorphisms in Chinese patients with systemic lupus erythematosus. J Clin Lab Anal (2006) 20:255-9. doi:10.1002/jcla.20151
129. Santos MJ, Fernandes D, Capela S, Da Silva JC, Fonseca JE. Interleukin-6 promoter polymorphism-174 G/C is associated with nephritis in Portuguese Caucasian systemic lupus erythematosus patients. Clin Rheumatol (2011) 30:409-13. doi:10.1007/s10067-010-1640-y
130. Lee YH, Lee HS, Choi SJ, Ji JD, Song GG. The association between interleukin-6 polymorphisms and systemic lupus erythematosus: a meta-analysis. Lupus (2012) 21:60-7. doi:10.1177/0961203311422711
131. Iwano M, Dohi K, Hirata E, Kurumatani N, Horii Y, Shiiki H, et al. Urinary levels of IL-6 in patients with active lupus nephritis. Clin Nephrol (1993) 40:16-21
132. Tsai CY, Wu TH, Yu CL, Lu JY, Tsai YY. Increased excretions of beta2-microglobulin, IL-6, and IL-8 and decreased excretion of Tamm-Horsfall glycoprotein in urine of patients with active lupus nephritis. Nephron (2000) 85:207-14. doi:10.1159/000045663
133. Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos-Diaz E. Renal expression of IL-6 and TNFalpha genes in lupus nephritis. Lupus (1998) 7:154-8. doi:10.1191/096120398678919949
134. Tsantikos E, Maxwell MJ, Putoczki T, Ernst M, Rose-John S, Tarlinton DM, et al. Interleukin-6 trans-signaling exacerbates inflammation and renal pathology in lupus-prone mice. Arthritis Rheum (2013) 65:2691-702. doi:10.1002/art.38061
135. Gurr W, Yavari R, Wen L, Shaw M, Mora C, Christa L, et al. A Reg family protein is overexpressed in islets from a patient with new-onset type 1 diabetes and acts as T-cell autoantigen in NOD mice. Diabetes (2002) 51:339-46. doi:10.2337/diabetes.51.2.339
136. Andriankaja OM, Barros SP, Moss K, Panagakos FS, Devizio W, Beck J, et al. Levels of serum interleukin (IL)-6 and gingival crevicular fluid of IL-1beta and prostaglandin E(2) among non-smoking subjects with gingivitis and type 2 diabetes. J Periodontol (2009) 80:307-16. doi:10.1902/jop.2009.080385
137. Lagathu C, Bastard JP, Auclair M, Maachi M, Capeau J, Caron M. Chronic interleukin-6 (IL-6) treatment increased IL-6 secretion and induced insulin resistance in adipocyte: prevention by rosiglitazone. Biochem Biophys Res Commun (2003) 311:372-9. doi:10.1016/j.bbrc.2003.10.013
138. Rotter V, Nagaev I, Smith U. Interleukin-6 (IL-6) induces insulin resistance in 3T3-L1 adipocytes and is, like IL-8 and tumor necrosis factor-alpha, overexpressed in human fat cells from insulin-resistant subjects. J Biol Chem (2003) 278:45777-84. doi:10.1074/jbc.M301977200
139. Dalla Vestra M, Mussap M, Gallina P, Bruseghin M, Cernigoi AM, Saller A, et al. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol (2005) 16(Suppl 1):S78-82. doi:10.1681/ASN.2004110961
140. Navarro JF, Milena FJ, Mora C, Leon C, Garcia J. Renal pro-inflammatory cytokine gene expression in diabetic nephropathy: effect of angiotensin-converting enzyme inhibition and pentoxifylline administration. Am J Nephrol (2006) 26:562-70. doi:10.1159/000098004
141. Kaur H, Chien A, Jialal I. Hyperglycemia induces toll like receptor 4 expression and activity in mouse mesangial cells: relevance to diabetic nephropathy. Am J Physiol Renal Physiol (2012) 303:F1145-50. doi:10.1152/ajprenal.00319.2012
142. Liu RY, Song X, Chen P, Lei Z, Miao J, Yi N, et al. Association between IL6-174G/C and cancer: a meta-analysis of 105,482 individuals. Exp Ther Med (2012) 3:655-64. doi:10.3892/etm.2012.454
143. Smith AJ, Humphries SE. Cytokine and cytokine receptor gene polymorphisms and their functionality. Cytokine Growth Factor Rev (2009) 20:43-59. doi:10.1016/j.cytogfr.2008.11.006
144. Papaoikonomou S, Tentolouris N, Tousoulis D, Papadodiannis D, Miliou A, Papageorgiou N, et al. The association of the 174G>C polymorphism of interleukin 6 gene with diabetic nephropathy in patients with type 2 diabetes mellitus. J Diabetes Complications (2013) 27:576-9. doi:10.1016/j.jdiacomp.2013.06.006
145. Karadeniz M, Erdogan M, Berdeli A, Yilmaz C. Association of interleukin-6-174 G>C promoter polymorphism with increased risk of type 2 diabetes mellitus patients with diabetic nephropathy in Turkey. Genet Test Mol Biomarkers (2014) 18:62-5. doi:10.1089/gtmb.2013.0357
146. Grigoryev DN, Liu M, Hassoun HT, Cheadle C, Barnes KC, Rabb H. The local and systemic inflammatory transcriptome after acute kidney injury. J Am Soc Nephrol (2008) 19:547-58. doi:10.1681/ASN.2007040469
147. Lemay S, Rabb H, Postler G, Singh AK. Prominent and sustained up-regulation of gp130-signaling cytokines and the chemokine MIP-2 in murine renal ischemia-reperfusion injury. Transplantation (2000) 69:959-63. doi:10.1097/00007890-200003150-00049
148. Yoshino J, Monkawa T, Tsuji M, Hayashi M, Saruta T. Leukemia inhibitory factor is involved in tubular regeneration after experimental acute renal failure. J Am Soc Nephrol (2003) 14:3090-101. doi:10.1097/01.ASN.0000101180.96787.02
149. Pecoits-Filho R, Heimburger O, Barany P, Suliman M, Fehrman-Ekholm I, Lindholm B, et al. Associations between circulating inflammatory markers and residual renal function in CRF patients. Am J Kidney Dis (2003) 41:1212-8. doi:10.1016/S0272-6386(03)00353-6
150. Takahashi T, Kubota M, Nakamura T, Ebihara I, Koide H. Interleukin-6 gene expression in peripheral blood mononuclear cells from patients undergoing hemodialysis or continuous ambulatory peritoneal dialysis. Ren Fail (2000) 22:345-54. doi:10.1081/JDI-100100878
151. Caglar K, Peng Y, Pupim LB, Flakoll PJ, Levenhagen D, Hakim RM, et al. Inflammatory signals associated with hemodialysis. Kidney Int (2002) 62:1408-16. doi:10.1111/j.1523-1755.2002.kid556.x
152. Bruun JM, Lihn AS, Verdich C, Pedersen SB, Toubro S, Astrup A, et al. Regulation of adiponectin by adipose tissue-derived cytokines: in vivo and in vitro investigations in humans. Am J Physiol Endocrinol Metab (2003) 285:E527-33. doi:10.1152/ajpendo.00110.2003
153. Huber SA, Sakkinen P, Conze D, Hardin N, Tracy R. Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol (1999) 19:2364-7. doi:10.1161/01.ATV.19.10.2364
154. Nishimoto N. Interleukin-6 as a therapeutic target in candidate inflammatory diseases. Clin Pharmacol Ther (2010) 87:483-7. doi:10.1038/clpt.2009.313
155. Mccarthy ET, Sharma M, Savin VJ. Circulating permeability factors in idiopathic nephrotic syndrome and focal segmental glomerulosclerosis. Clin J Am Soc Nephrol (2010) 5:2115-21. doi:10.2215/CJN.03800609